Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...

ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being ...

One investigation discussed during the call involves sales reps in China allegedly changing genetic testing results to secure reimbursement for Tagrisso.

associate director of the Metastatic Breast Cancer Program, Dana-Farber Cancer Institute, discusses findings from an analysis ...

New study introduces a simple blood test to detect early lung damage in cancer patients receiving novel therapy with antibody ...

The "Cancer Antibody Drug Conjugates Market Size, Drugs Approval, Price, Sales & Clinical Trials Insight 2030" report has been added to ResearchAndMarkets.com's offering. Antibody drug conjugates ...

Some of the major updates include the approval of acalabrutinib (Calquence) for first-line treatment of mantle cell lymphoma, the FDA’s priority review of fam-trastuzumab deruxtecan-nxki (T-DXd; ...

Under this two-hit model, Brugge says, one normal copy of BRCA1 ought to be able to carry out DNA repair even when the other ...

A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and ...

The 2024 Innovator Award will cover four years of Ramanujam and her team’s work to reduce the burdens of cancer treatments on ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...